Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus BioSciences to launch Humira biosimilar at $995 per carton
09:24am, Thursday, 01'st Jun 2023
Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's blockbuster arthritis drug Humira in July at a list price of $995 per carton, representing a discount of about
FDA flags issues at Coherus partner's China manufacturing site for cancer drug
01:37pm, Wednesday, 31'st May 2023
Coherus BioSciences Inc said on Wednesday that the U.S. Food and Drug Administration (FDA) flagged three observations at its partner Shanghai Junshi Biosciences Ltd's manufacturing site in China for i
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
08:56am, Friday, 26'th May 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Coherus BioSciences, Inc. (CHRS) Q1 2023 Earnings Call Transcript
09:40pm, Monday, 08'th May 2023
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Marek Ciszewski - Investor Relations Denny Lanfear - Chief Executive Officer There
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
07:02pm, Monday, 08'th May 2023
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.24 per share a year ago.
Coherus BioSciences to Present at Upcoming Investor Conferences in May
04:30pm, Thursday, 04'th May 2023
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor confere
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
04:07pm, Monday, 01'st May 2023
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market cl
Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade)
08:00am, Friday, 28'th Apr 2023
Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade).
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
02:45pm, Friday, 14'th Apr 2023
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
Hundreds more tech, biotech layoffs hit Bay Area, Google real estate ally cuts jobs
02:08pm, Monday, 13'th Mar 2023
About 600 more tech and biotech layoffs rocked the Bay Area job market in a fresh round of cutbacks that suggest the staffing reductions in the region have yet to run their course, new state governmen
Coherus BioSciences, Inc. (CHRS) Q4 2022 Earnings Call Transcript
10:22pm, Monday, 06'th Mar 2023
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Marek Ciszewski - SVP, IR Denny Lanfear - CEO Theresa Lavallee - Chief Developme
Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Monday, 06'th Mar 2023
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 6.25% and 0.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences to Present at Upcoming Investor Conferences in March
08:25am, Wednesday, 01'st Mar 2023
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferenc
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
08:25am, Tuesday, 28'th Feb 2023
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be rel
Competition Coming For AbbVie's Blockbuster Humira
01:08am, Thursday, 16'th Feb 2023
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
